Skip to main content
  • Clinical Trials
  • SPRinstitute™ Library
Menu
Home
SPR
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us

SPR is now part of Medtronic.

More Info

Press Releases

Breadcrumb

  1. Home
  2. Press Releases

All Press Releases

FDA-clears-SPRINT-2018 FDA-clears-SPRINT-2018

FDA clears SPR's non-opioid SPRINT endura and extensa peripheral nerve stimulation systems for pain management

Press releases + media
2017-series-c-announcement 2017-series-c-announcement

SPR secures $25 million in Series C financing

Press releases + media
josh-boggs-2017-announcement josh-boggs-2017-announcement

SPR promotes Dr. Joseph Boggs to SVP of research and development

Press releases + media
2017-6M-DoD-Award 2017-6M-DoD-Award

SPR awarded $6M contract from the United States Department of Defense to advance non-opioid pain relief therapy

Press releases + media
spr logo spr logo

SPR appoints Michael P. Chuisano to Board of Directors

Press releases + media
dave-youngberg-2017-announcement dave-youngberg-2017-announcement

SPR names Dave Youngberg Vice President of Sales

Press releases + media

Pagination

  • Previous page ‹
  • …
  • Page2
  • Page3
  • Page4
  • Page5
  • Current page6
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us
  • Compliance
  • Consumer Health Data Request Form
  • CPRA Requests
  • FCOI Policy
  • Indications for Use
  • MRI Safety Information
  • Patent Information
  • Product Terms and Conditions
  • Safety Information
  • Trademarks
  • Billing Portal
Home
  • Consumer Health Data and Information Privacy Policy
  • Terms of Use
Visit us on Facebook
Visit us on Twitter
Visit us on Instagram
Visit us on YouTube
Visit us on LinkedIn

The SPRINT Peripheral Nerve Stimulation (PNS) System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. It is intended to be implanted for up to 60 days and provide sustained pain relief for up to 3 months after the end of treatment. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Refer to Indications for Use for the SPRINT System’s additional indication referencing acute pain. 

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View references for support of all claims.

Product and brand names/logos are registered or common law trademarks of SPR.

© 2026 SPR. All Rights Reserved.